**Table e-2** Patients with AEs leading to treatment discontinuation in the OCR all-exposure populationa

|  |  |
| --- | --- |
| **MedDRA SOC**  **MedDRA preferred term** | **Number of patients** |
| **Overall total number of patients** | **181** |
| **Neoplasms benign, malignant and unspecified  (including cysts and polyps)**  Invasive ductal breast carcinoma  Breast cancer  Malignant melanoma  Papillary thyroid cancer  Prostate cancer  Adenocarcinoma of colon   Anaplastic large-cell lymphoma  Basal cell carcinoma  Carcinoma *in situ* of penis   Cervix carcinoma stage II  Chondrosarcoma  Endometrial adenocarcinoma  Endometrial cancer  Hypergammaglobulinemia benign monoclonal   Invasive breast carcinoma  Lobular breast carcinoma *in situ*  Lung neoplasm malignant  Malignant fibrous histiocytoma  Metastatic malignant melanoma  Nodular melanoma  Pancreatic carcinoma metastatic  Renal cell carcinoma  Squamous cell carcinoma  Transitional cell carcinoma | **40**  8 5 4 2 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 |
| **Injury, poisoning and procedural complications**  Infusion-related reaction  Lumbar vertebral fracture  Subdural hematoma | **35** 33 1 1 |
| **Infections and infestations**  Urinary tract infection  Herpes zoster  Infectionb  Sepsis  Septic shock  Acute hepatitis C  Anal abscess  Bacterial vaginosis  Bronchitis  Cellulitis  *Clostridium difficile* colitis   Coccidioidomycosis  Large intestine infection  Latent tuberculosis  Mastoiditis   Esophageal candidiasis  Periodontitis  Pneumonia   Pulmonary tuberculoma  Viral infection | **27** 4 2 2 2 2 1 1 1 1 1 1 1 1 1 1 1 1 1  1  1 |
| **Psychiatric disorders**  Depression  Anxiety  Completed suicide  Delusion  Depressive symptom  Hallucination  Mental disorder  Suicidal ideation  Suicide attempt | **13** 3 2 2 1 1 1 1 1  1 |
| **Skin and subcutaneous tissue disorders**  Rash   Alopecia  Asteatosis  Decubitus ulcer  Dermatitis allergic  Dermatitis bullous  Erythema nodosum  Guttate psoriasis  Interstitial granulomatous dermatitis  Pruritis allergic  Skin lesion | **12** 2 1 1 1 1 1 1 1 1 1 1 |
| **Investigations**  Neutrophil count decreased  B lymphocyte count decreased  Blood creatine increased  Blood immunoglobulin G decreased  CD4 lymphocytes decreased  Electrocardiogram QT prolonged  Gamma-glutamyltransferase increased  Transaminases increased | **9** 2 1 1 1 1 1 1 1 |
| **Gastrointestinal disorders**  Crohn’s disease  Colitis  Colitis ulcerative  Diarrhea  Enterocolitis | **8** 4 1 1 1 1 |
| **General disorders and administration site conditions**  Fatigue  Asthenia  Chest pain  Chills  Influenza-like illness  Pyrexia | **7** 2 1 1 1 1 1 |
| **Nervous system disorders**  Multiple sclerosis relapse  Headache  Optic neuritis  Secondary progressive multiple sclerosis  Speech disorder | **6** 2 1 1 1 1 |
| **Musculoskeletal and connective tissue disorders**  Arthralgia  Osteonecrosis  Pain in extremity  Psoriatic arthropathy  Seronegative arthritis | **5** 1 1 1 1 1 |
| **Blood and lymphatic system disorders**  Lymphocytosis  Lymphopenia  Neutropenia | **3** 11 1 |
| **Hepatobiliary disorders**  Hepatitis  Hepatitis fulminant  Portal vein thrombosis | **3** 1 1 1 |
| **Immune system disorders**  Hemophagocytic lymphohistiocytosis  Hypersensitivity  Hypogammaglobulinemia | **3** 1 1 1 |
| **Metabolism and nutrition disorders**  Diabetes mellitus inadequate control  Hypoproteinemia  Lactic acidosis | **3** 1 1 1 |
| **Cardiac disorders**  Aortic valve incompetence  Congestive cardiomyopathy | **2** 1 1 |
| **Reproductive system and breast disorders**  Cervical dysplasia  Metrorrhagia | **2** 1 1 |
| **Respiratory, thoracic and mediastinal disorders**  Dysphonia  Sinus congestion | **2** 1 1 |
| **Eye disorders**  Vitreous floaters | **1** 1 |

Investigator text for AEs was encoded using MedDRA version 22.1. Multiple occurrences of the same AE in 1 patient are counted only once.  
a Includes patients who received any dose of OCR during the CTP and associated OLE periods of the phase 2 and phase 3 studies, including patients originally randomized to comparator (IFN β-1a or placebo) who switched to open-label OCR treatment, plus VELOCE, CHORDS, CASTING, OBOE, ENSEMBLE, CONSONANCE, and LIBERTO.   
b Reported terms: Infection-suspicion, WBC count 18.4 x 109/L, and Infectious syndrome of unknown cause.  
AE = adverse event; CTP = controlled treatment period; IFN = interferon; MedDRA = Medical Dictionary for Regulatory Activities; OCR = ocrelizumab; OLE = open-label extension; SOC = system organ class; WBC = white blood cell.